Interpretation of updated international guidelines for diagnosis and treatment of gastroenter-opancreatic neuroendocrine neoplasms.
10.3760/cma.j.cn.441530-20210823-00342
- Author:
Luo Hai CHEN
1
;
Jie CHEN
2
Author Information
1. Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510085, China.
2. Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510085, China Chen Jie now is working at the Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China.
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Guideline;
Neuroendocrine neoplasms, gastroenteropancreatic;
Treatment
- MeSH:
Gastrointestinal Neoplasms/therapy*;
Humans;
Incidence;
Neoplasm Staging;
Neuroendocrine Tumors/therapy*
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(10):843-848
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of neuroendocrine neoplasms (NEN) is continuously increasing with gastrointestinal tract and pancreas being the most common primary sites. Currently, the guidelines proposed by European Neuroendocrine Tumor Society (ENETS), National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO) and North American Neuroendocrine Tumor Society (NANETS) are being widely applied. Among these, ENETS and NANETS guidelines were proposed in 2017 while ESMO and NCCN recently updated their guidelines for gastroenteropancreatic NEN in 2020 and 2021, respectively. This article interprets the diagnosis and treatment of gastroenteropancreatic NEN based on the newly updated ESMO and NCCN guidelines. The diagnosis of gastroenteropancreatic NEN depends on histological assessment including morphological evaluation, grading and immunohistochemistry results. Combination of different imaging methods can help determine tumor staging and risk assessment. Decision-making of treatment and follow-up strategies is based on primary tumor site, tumor classification, tumor grade, tumor type, functional status etc.
